

ADAP Advisory Workgroup
Conference Call Meeting Minutes
August 7, 2008

In Attendance: Lorraine Wells (Bureau of HIV/AIDS-HQ), Joe May (Bureau of HIV/AIDS-HQ), Dr. Ernesto Lamadrid (Bureau of HIV/AIDS-HQ), Stephanie Brown (Bureau of HIV/AIDS-HQ), Gayle Mclaughlin (Bureau of HIV/AIDS-HQ), Dr. Jasper Watkins (Statewide Pharmaceutical Services), Dr. Brandon Brantley (Statewide Pharmaceutical Services), Elicia Coley (AHCA), Jerry Stambaugh (AGH), Joey Wynn (member), Joseph Lennox-Smith (member), Mike Ehren (Broward CHD Pharmacy), Susan Kramer (St. Lucie CHD), Jim Roth (HAPC), Mike Wallace (Citrus CHD), and Butch McKay (member).

Dr. Jeff Beal and Dr. Allison Nist were unable to attend.

The conference call was convened on August 7, 2008 at 2:30p.m. There were opening comments by Lorraine Wells and then introductions were made around the room.

Joe May began by sending greetings from Tom Liberti. Joe also noted that all comments and concerns regarding reformation of the workgroup were heard and noted by the Bureau's management staff; in addition, Tom Liberti has been and will be involved in all decisions made.

Utilization Update:

As a follow-up to the previous conference call, Dr. Ernesto Lamadrid provided a utilization report for Lexapro. Dr. Lamadrid informed that there are currently 106 clients on Lexapro and the total cost to service these clients is about \$4,000. As a result of these figures, Dr. Lamadrid sees no problem continuing treatment with Lexapro, as opposed to a generic alternative.

Formulary Additions:

Dr. Lamadrid discussed new drugs that are ready for addition to the ADAP formulary. These medications include, Clotrimazole (Mycelex), an anti-fungal; Famciclovir (Famvir), an anti-viral; Imiquimod (Aldara) used for topical treatment of warts; Ketoconazole cream and shampoo (Nizoral), used as an anti-fungal; Levofloxacin (Levaquin) a bacterial infection treatment medication and Moxifloxacin (Avelox), used to treat pneumonia and respiratory infections. Additionally, Omeprazole (Prilosec) a reflux disease treatment medication; and Valacyclovir (Valtrex), an anti-viral used to treat herpes. There are also three anti-psychotics being added: Ziprasidone (Geodon), Risperidone (Risperdal), and Aripiprazole (Abilify). Lastly Mupirocin (Bactroban), an antibiotic ointment, will be added.

Concerns were expressed by members of the workgroup regarding the cost efficiency of adding some medications. As a result, some members felt that a cost analysis should be performed to evaluate possible cost savings for Valtrex and Famvir; for example, generic alternatives. Dr. Lamadrid will provide scientific data to support the efficacy of Valtrex as opposed to Acyclovir. Dr. Watkins from the DOH pharmacy expressed

concerns about the possibility of promoting drug resistance with the new antibiotics. Members agreed that the prescribing physicians are versed in these matters.

Workgroup Reformation

Lorraine thanked all workgroup members for their feedback related to the future composition and role of the workgroup. Lorraine also explained that all decisions are made collaboratively by Bureau and program leadership. Lorraine reiterated that the purpose of restructuring the formulary workgroup is to add diverse representation and establish clear guidelines, roles, and expectations of the workgroup members. Lorraine added that concerns of ensuring continuity and keeping historical perspective were noted. The restructure has been designed to address most, if not all of the concerns shared.

There also have been concern/discussion about whether the workgroup restructure has been shared with others that have inquired. Lorraine stated that the information would not be brought to the general public for consumption prior to sharing with the workgroup.

A charter has been developed which describes the role and function of the formulary workgroup. It allows for at least 14 voting seats, not including Department of Health staff. All current workgroup members are welcome to reapply. A letter from the Bureau of HIV/AIDS chief, Tom Liberti, will be sent acknowledging the work of the existing workgroup as well as information on the restructure. The packet will include a letter from Tom Liberti and an application. Bureau staff will post the application for the community shortly after packages are sent to workgroup members. Applications will be reviewed in October and selections will be made and provided to Tom Liberti for approval. A notice of invitation will then be sent to newly appointed members. Finally, a full meeting is expected to take place in early December; this meeting will serve as an orientation.

Respectfully submitted,
September 10, 2008